Monitoring Public Health Impact of HPV Vaccination on RRP

  • Vidisha Singh
  • Elissa Meites
  • Adam Klein


Recurrent respiratory papillomatosis (RRP) is a rare disease resulting from human papillomavirus (HPV) infection. Estimates of disease burden may vary due to non-standardized study methodology. Monitoring of RRP can characterize RRP burden, identify risk factors and susceptible populations, detect rare complications, identify opportunities for prevention, and evaluate current therapies and public health interventions. Since the 2006 introduction of HPV vaccine in the United States, monitoring may be useful for measuring vaccine impact on reducing or preventing RRP. RRP monitoring may also help identify opportunities to improve quality of life for active cases and reduce overall costs associated with disease management. Potential methods for monitoring RRP include national surveillance systems, nationally representative health surveys, registries and collaboratives, and administrative claims databases. Ideally, a national RRP registry or database may enable assessment of HPV vaccine impact on RRP burden in countries with HPV vaccination programs.


Recurrent respiratory papillomatosis Laryngeal papilloma Human papillomavirus HPV vaccine Public health surveillance Disease monitoring Rare diseases 



Quadrivalent HPV vaccine


Nonavalent HPV vaccine


Advisory Committee on Immunization Practices


Adult onset recurrent respiratory papillomatosis


Centers for Disease Control and Prevention


Centers for Medicare and Medicaid Services


Current Procedural Terminology


Council of State and Territorial Epidemiologists


Deoxyribonucleic acid


Ear, nose, and throat


Eastern Virginia Medical School


Human papillomavirus


International Classification of Disease


Juvenile onset recurrent respiratory papillomatosis


Men who have sex with men


National Center for Health Statistics


National Health and Nutrition Examination Survey


National Institutes of Health


National Notifiable Disease Surveillance System


Positive predictive values


Recurrent respiratory papillomatosis


United Kingdom


United States



The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.


  1. Adams D, Fullerton K, Jajosky R, Sharp P, Onweh D, Schley A, et al. Summary of Notifiable Infectious Diseases and Conditions - United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;62(53):1–122.Google Scholar
  2. Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg. 1999;125(7):743–8.Google Scholar
  3. Armstrong LR, Preston EJ, Reichert M, Phillips DL, Nisenbaum R, Todd NW, et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis. 2000;31(1):107–9.Google Scholar
  4. Bomholt A. Juvenile laryngeal papillomatosis. An epidemiological study from the Copenhagen region. Acta Otolaryngol. 1988;105(3-4):367–71.Google Scholar
  5. Bomholt A. Laryngeal papillomas with adult onset. An epidemiological study from the Copenhagen region. Acta Otolaryngol. 1988;106(1-2):140–4.Google Scholar
  6. Buchinsky FJ, Derkay CS, Leal SM, Donfack J, Ehrlich GD, Post JC. Multicenter initiative seeking critical genes in respiratory papillomatosis. Laryngoscope. 2004;114(2):349–57.Google Scholar
  7. Campisi P, Hawkes M, Simpson K, Canadian Juvenile Onset Recurrent Respiratory Papillomatosis Working Group. The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database. Laryngoscope. 2010;120(6):1233–45.Google Scholar
  8. Carvalho CM, Huot L, Charlois AL, Khalfallah SA, Chapuis F, Froehlich P. Prognostic factors of recurrent respiratory papillomatosis from a registry of 72 patients. Acta Otolaryngol. 2009;129(4):462–70.Google Scholar
  9. Centers for Disease Control and Prevention. 2016 Nationally Notifiable Conditions. Available from: Scholar
  10. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):630–2.Google Scholar
  11. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey Atlanta, GA: Department of Health & Human Services; November 2015. Available from: Scholar
  12. Centers for Disease Control and Prevention. Chapter 11: Human Papillomavirus. In: Hamborsky J, Kroger A, Wolfe S, editors. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015. p. 175–86.Google Scholar
  13. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705–8.Google Scholar
  14. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg. 1995;121(12):1386–91.CrossRefPubMedGoogle Scholar
  15. Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope. 2001;111(1):57–69.Google Scholar
  16. Donne A, Keltie K, Cole H, Sims A, Patrick H, Powell S. Prevalence and management of recurrent respiratory papillomatosis (RRP) in the UK: cross sectional study. Clin Otolaryngol. 2016;42:86–91.Google Scholar
  17. Gelbard A, Donovan DT, Ongkasuwan J, Nouraei SA, Sandhu G, Benninger MS, et al. Disease homogeneity and treatment heterogeneity in idiopathic subglottic stenosis. Laryngoscope. 2016;126(6):1390–6.Google Scholar
  18. Gostin LO. Public health law in a new century: part II: public health powers and limits. JAMA. 2000;283(22):2979–84.CrossRefPubMedGoogle Scholar
  19. Ivankovich MB, Leichliter JS, Douglas JM Jr. Measurement of sexual health in the U.S.: an inventory of nationally representative surveys and surveillance systems. Public Health Rep. 2013;128(Suppl 1):62–72.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24(Suppl 3):S3/35–41.Google Scholar
  21. Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS. 2010;118(6–7):450–4.Google Scholar
  22. Lee LM, Thacker SB. Centers for Disease Control and Prevention. The cornerstone of public health practice: public health surveillance, 1961–2011. MMWR Suppl. 2011;60(4):15–21.PubMedGoogle Scholar
  23. Lindeberg H, Elbrond O. Laryngeal papillomas: clinical aspects in a series of 231 patients. Clin Otolaryngol Allied Sci. 1989;14(4):333–42.CrossRefPubMedGoogle Scholar
  24. Lindeberg H, Elbrond O. Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965-1984. Clin Otolaryngol Allied Sci. 1990;15(2):125–31.CrossRefPubMedGoogle Scholar
  25. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1–24.Google Scholar
  26. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1–30.Google Scholar
  27. Marsico M, Mehta V, Chastek B, Liaw KL, Derkay C. Estimating the incidence and prevalence of juvenile-onset recurrent respiratory papillomatosis in publicly and privately insured claims databases in the United States. Sex Transm Dis. 2014;41(5):300–5.Google Scholar
  28. Meites, E, Workowski, KA. Chapter 12: Public Health and Prevention. In: Skolnik, NS, Clouse, AL, Woodward, J, editors. Sexually Transmitted Diseases: A Practical Guide for Primary Care. 2nd ed. New York: Humana Press; 2013. p 161–171.Google Scholar
  29. National Institutes of Health. List of registries. In: NIH clinical research trials and you. Bethesda, MD. Aug 2016.
  30. Novakovic D, Cheng AT, Cope DH, Brotherton JM. Estimating the prevalence of and treatment patterns for juvenile onset recurrent respiratory papillomatosis in Australia pre-vaccination: a pilot study. Sex Health. 2010;7(3):253–61.Google Scholar
  31. Nsubuga P, White ME, Thacker SB, Anderson MA, Blount SB, Broome CV, et al. Public health surveillance: a tool for targeting and monitoring interventions. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Disease control priorities in developing countries. 2nd ed. Washington, DC: World Bank Publications; 2006.Google Scholar
  32. Omland T, Akre H, Vardal M, Brondbo K. Epidemiological aspects of recurrent respiratory papillomatosis: a population-based study. Laryngoscope. 2012;122(7):1595–9.Google Scholar
  33. Reeves WC, Ruparelia SS, Swanson KI, Derkay CS, Marcus A, Unger ER. National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2003;129(9):976–82.Google Scholar
  34. Riley GF. Administrative and claims records as sources of health care cost data. Med Care. 2009;47(7 Suppl 1):S51–5.Google Scholar
  35. Ruiz R, Achlatis S, Verma A, Born H, Kapadia F, Fang Y, et al. Risk factors for adult-onset recurrent respiratory papillomatosis. Laryngoscope. 2014;124(10):2338–44.Google Scholar
  36. Shah KV, Stern WF, Shah FK, Bishai D, Kashima HK. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis J. 1998;17(5):372–6.CrossRefPubMedGoogle Scholar
  37. Singh V, Querec T, Patton M, Unger ER, Derkay C, Markowitz LE, Meites E. Monitoring for Juvenile Onset Recurrent Respiratory Papillomatosis — United States, 2015–16. Poster presented at: Pediatric Academic Societies Meeting; May 6-9, 2017; San Francisco, CA.Google Scholar
  38. Sirken MG, Hirsch R, Mosher W, Moriarity C, Sonnenfeld N. Centers for Disease Control and Prevention. Changing methods of NCHS surveys: 1960–2010 and beyond. MMWR Suppl. 2011;60(4):42–8.Google Scholar
  39. Strong MS, Vaughan CW, Cooperband SR, Healy GB, Clemente MA. Recurrent respiratory papillomatosis: management with the CO2 laser. Ann Otol Rhinol Laryngol. 1976;85(4 Pt 1):508–16.CrossRefPubMedGoogle Scholar
  40. Thacker SB, Berkelman RL. Public health surveillance in the United States. Epidemiol Rev. 1988;10:164–90.CrossRefPubMedGoogle Scholar
  41. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis. 2002;35(Suppl 2):S210–24.Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Division of Viral DiseasesNational Center for Immunization and Respiratory Diseases, Centers for Disease Control and PreventionAtlantaUSA
  2. 2.Department of Otolaryngology-HNS, Emory Voice CenterEmory University School of MedicineAtlantaUSA

Personalised recommendations